Nektar Therapeutics
![Nektar Therapeutics](https://api.admiralmarkets.com/trade_icons/bright-128/NKTR.png)
Suletud
1.14 1.79
Ülevaade
Aktsiahinna muutus
24h
Min
1.14
Max
1.17
Sissetulek | -46M |
---|---|
Müük | -259K 24M |
Aktsiakasum | -0.22 |
Kasumimarginaal | -189.848 |
Töötajad | 137 |
EBITDA | -32M |
Soovitused | Osta |
---|---|
12 kuu keskmine prognoos | +78.57 upside |
Järgmine tulemuste avaldamine | 5. nov 2024 |
---|
Turukapital | -20M 230M |
---|---|
Eelmine avamishind | -0.65 |
Eelmine sulgemishind | 1.14 |
Tehniline skoor
By Trading Central
Kindlus
Very Strong Bearish Evidence
Nektar Therapeutics Graafik
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Nektar Therapeutics Prognoos
Hinnasiht
By TipRanks
78.57% tõus
12 kuu keskmine prognoos
Keskmine 2 USD 78.57%
Kõrge 2 USD
Madal 2 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Nektar Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.